|
Technology
|
A New Era For Alzheimer’s Disease May Be Around The Corner
2024-08-22 23:55:08
Health
Medicine
Science

A New Era For Alzheimer’s Disease May Be Around The Corner

Image used under license from Shutterstock.com

New Alzheimer's drugs like donanemab and lecanemab can modestly slow cognitive decline, but may cause brain bleeds. Blood tests detecting amyloid and tau biomarkers may enable earlier treatment.

Vaccines targeting multiple disease proteins and drugs that target aging-related pathways are being developed. Lecanemab, the first novel Alzheimer's drug in 20 years, slows decline but faces high costs and funding challenges.

Donanemab is also being assessed, and numerous potential treatments are in development. Despite controversies, effective treatments for Alzheimer's are still elusive as the disease affects millions worldwide.

The press radar on this topic:

forbes
21. August 2024 um 13:00

A New Era For Alzheimer’s Disease May Be Around The Corner

Technology
New Alzheimer's drugs like donanemab and lecanemab can modestly slow cognitive decline, but face risks, with over a third of donanemab patients experiencing brain bleeds in the TRAILBLAZER-ALZ 2 trial. Blood tests detecting amyloid and tau biomarkers, including the JAMA-described ptau-217 test, may enable earlier treatment, as demonstrated by a National Institute on Aging-funded study. Vaccines targeting multiple disease proteins are in development, with Prothena's candidate aiming for both am..
Yahoo!
22. August 2024 um 13:42

All you need to know about the Alzheimer’s drug which was rejected for NHS use

Economy
Lecanemab, an antibody drug approved by MHRA but rejected by NICE for NHS use due to high costs, has been shown to slow early-stage Alzheimer's by removing amyloid and slowing cognitive decline 4-6 months, though some patients experienced infusion reactions and 3 deaths (<0.2%) occurred. Around 70,000 adults in England would have been eligible, and companies like Re:Cognition Health will offer private lecanemab treatments. Meanwhile, Donanemab is being assessed, and 130 potential treatments and..
Liberation
22. August 2024 um 15:47

Alzheimer: The British drug regulator approves a treatment rejected by the EU

Politics
Leqembi, a treatment for Alzheimer's disease developed by Eisai and Biogen, has been approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) but rejected by the National Institute for Health and Care Excellence (Nice), which believes its modest benefits do not justify the significant costs and heavy monitoring required for the NHS. Despite these controversies, research is struggling to find effective treatments for Alzheimer's, which affects tens of millions of people w..
Bio & Medicine News - Nanobiology News, Nanomedicine News, Nanotech News, Nanotechnology News
22. August 2024 um 16:24

Alzheimer's drug may someday help save lives by inducing a state of 'suspended animation'

Technology
Donepezil, an Alzheimer's drug, induced a hibernation-like state in tadpoles, which could extend the "Golden Hour" after trauma. The team previously used SNC80 but it causes seizures. They used a machine learning algorithm, NeMoCad, to identify donepezil, and encapsulated it in lipid nanocarriers to reduce toxicity, as part of the DARPA Biostasis Program. Donepezil has been shown to protect neurons in Alzheimer's disease, and the central nervous system is known to mediate hibernation in other..
CW

Account

Waiting list for the personalized area


Welcome!

InfoBud.ai

infobud.ai is an AI-driven news aggregator that simplifies global news, offering customizable feeds in all languages for tailored insights into tech, finance, politics, and more. It provides precise, relevant news updates, overcoming conventional search tool limitations. Due to the diversity of news sources, it provides precise and relevant news updates, focusing entirely on the facts without influencing opinion. Read moreExpand

Spotlighting today's most mentioned stocks in the media. Uncover the stories making waves in the stock market:

A closer look at the individuals who are leading today's news narratives. Find out what makes them the center of attention.

Exploring the five locations receiving the most media attention in the last 24 hours. Discover what puts these places in the global spotlight

Your World, Tailored News: Navigate The News Jungle With AI-Powered Precision!

News

All News
Politics
Technology
Economy
Business
Climate

About

About Us
Team + Mission

Legal

Cookie Settings
Disclaimer
Legal Notice
Data Privacy

Contact

Contact